Myelofibrosis interim data is seriously good: -TSS improved to 80% -Significant spleen volume reduction
I can’t believe we are letting the results be overshadowed by an expected or unexpected cap raise.
SNT is funded now. They literally had 1 quarter of cash at the last 4c. You can’t negotiate with big pharma if you are running out of cash, the ASX requires that companies cleanse of all material nonpublic information so you wouldn't be able to get deep in a process and then raise cash, forcing snt to take a shit deal. It would literally blow up any deal.
It won’t matter though, because it’s normal for a P2C/3 biotech to be valued at $300-500m and the the cap rise will be oversubscribed I’m sure. Additionally cap raise was done at a 10% premium to the 30 day WVAP - not a bad outcome!
I have been part of SNT on and off since 2019 (PXS). And it’s hurt, but SNT isn’t a normal biotech anymore and I’ve been buying.
good luck all!
SNT Price at posting:
6.7¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)